Trial Profile
A retrospective, observational study of dasatinib, imatinib, nilotinib in patients with chronic phase chronic myeloid leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2019
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results (n=419) of newly diagnosed CP-CML patients treated with Imatinib first-line 400 mg daily presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 12 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.